Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

    NEXT STORY
    Resuscitation Devices Market Was Worth US$ 6.2 Billion in 2019 and is Expected to Reach US$ 10.3 Billion at a CAGR of 4.9%
    PREV STORY
    Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock

    author_avatar
    NASDAQ Market News

    Morris Animal Foundation awards 16 grants to fund diverse set of equine studies

    DENVER, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Morris Animal Foundation, dedicated to improving animal ...

    author_avatar
    NASDAQ Market News

    Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)

    author_avatar
    NASDAQ Market News